J. C. Wagner, C. A. Sleggs, and P. Marchand, Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province, Br J Ind Med, vol.17, pp.260-71, 1960.

A. R. Haas and D. H. Sterman, Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies, Clin Chest Med, vol.34, pp.99-111, 2013.

I. Opitz, Management of malignant pleural mesothelioma-The European experience, Journal of thoracic disease, vol.6, issue.2, pp.238-52, 2014.

I. Opitz, R. Bueno, and E. Lim, Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know, Eur J Cardiothorac Surg, vol.46, pp.602-608, 2014.

T. Treasure, L. Lang-lazdunski, and D. Waller, Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study, Lancet Oncol, vol.12, pp.763-72, 2011.

A. Reid, N. H. De-klerk, and C. Magnani, Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis, Thorax, vol.69, pp.843-50, 2014.

A. L. Frank and T. K. Joshi, The global spread of asbestos, Ann Glob Health, vol.80, pp.257-62, 2014.

S. L. Leong, R. Zainudin, and L. Kazan-allen, Asbestos in Asia. Respirology, 2015.

C. Bianchi and T. Bianchi, Global mesothelioma epidemic: Trend and features. Indian journal of occupational and environmental medicine, vol.18, pp.82-90, 2014.

D. Jean, L. Pimpec-barthes, F. Andujar, and P. , Thoracic Neoplasia-Mesothelioma, Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, pp.2690-700, 2014.

F. Guida, M. A. Billon-galland, and I. Stucker, Effets sur la santé des fibres minérales artificielles. ECM -Pathologie professionnelle et de l'environnement, vol.9, pp.1-8, 2014.

M. Carbone, B. H. Ly, and R. F. Dodson, Malignant mesothelioma: facts, myths, and hypotheses, J Cell Physiol, vol.227, pp.44-58, 2012.

P. A. Rascoe, D. Jupiter, and X. Cao, Molecular pathogenesis of malignant mesothelioma, Expert Rev Mol Med, vol.14, p.12, 2012.

P. G. Betta, C. Magnani, and T. Bensi, Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting, Arch Pathol Lab Med, vol.136, pp.450-457, 2011.

M. C. Cabrera, R. E. Hollingsworth, and E. M. Hurt, Cancer stem cell plasticity and tumor hierarchy, World journal of stem cells, vol.7, pp.27-36, 2015.

M. Shackleton, E. Quintana, and E. R. Fearon, Heterogeneity in cancer: cancer stem cells versus clonal evolution, Cell, vol.138, pp.822-831, 2009.

D. Hanahan and L. M. Coussens, Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer Cell, vol.21, pp.309-331, 2012.

A. N. Husain, T. Colby, and N. Ordonez, Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, 2013.

D. Jean, J. Daubriac, L. Pimpec-barthes, and F. , Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

G. J. Gordon, G. N. Rockwell, and R. V. Jensen, Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005.

C. D. Hoang, D. 'cunha, J. Kratzke, and M. G. , Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004.

A. De-reynies, M. C. Jaurand, and A. Renier, Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-tomesenchymal transition, Clin Cancer Res, vol.20, pp.1323-1357, 2014.

M. Bott, M. Brevet, and B. S. Taylor, The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011.

D. Jean, E. Thomas, and M. E. , Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00531343

A. Tallet, J. C. Nault, and A. Renier, Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02478602

G. Guo, J. Chmielecki, and C. Goparaju, Whole exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma, Cancer Res, 2015.

M. Lo-iacono, M. V. Righi, and L. , Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study, J Thorac Oncol, vol.10, pp.492-501, 2015.

A. Miyanaga, M. Masuda, and K. Tsuta, Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing, J Thorac Oncol, vol.10, pp.844-51, 2015.

M. A. Lemmon and J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell, vol.141, pp.1117-1151, 2010.

Y. Son, S. Kim, and H. T. Chung, Reactive oxygen species in the activation of MAP kinases, Methods in enzymology, vol.528, pp.27-48, 2013.

J. G. Edwards, D. E. Swinson, and J. L. Jones, EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma, Lung Cancer, vol.54, pp.399-407, 2006.

Y. Enomoto, T. Kasai, and M. Takeda, Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma, J Clin Pathol, vol.65, pp.522-529, 2012.

R. Gaafar, A. Bahnassy, and I. Abdelsalam, Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma, Lung Cancer, vol.70, pp.43-50, 2010.

O. Rena, L. R. Boldorini, and E. Gaudino, Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: Prognostic correlations, J Surg Oncol, vol.104, pp.701-706, 2011.

J. F. Cortese, A. L. Gowda, and A. Wali, Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma, Int J Cancer, vol.118, pp.521-523, 2006.

R. Mezzapelle, U. Miglio, and O. Rena, Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma, Br J Cancer, vol.108, pp.1743-1752, 2013.

V. Velcheti, Y. Kasai, and A. K. Viswanathan, Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma, J Thorac Oncol, vol.4, p.559, 2009.

T. Shukuya, M. Serizawa, and M. Watanabe, Identification of actionable mutations in malignant pleural mesothelioma, Lung Cancer, vol.86, pp.35-40, 2014.

V. Schildgen, O. Pabst, and R. L. Tillmann, Diagnostic molecular pathology : the American journal of surgical pathology, 2014.

M. Brevet, S. Shimizu, and M. J. Bott, Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy, J Thorac Oncol, vol.6, pp.864-74, 2011.

P. Andujar, J. C. Pairon, and A. Renier, Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis, vol.28, pp.323-354, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02478590

A. Y. Lee, D. J. Raz, and B. He, Update on the molecular biology of malignant mesothelioma, Cancer, vol.109, pp.1454-61, 2007.

B. I. Gerwin, J. F. Lechner, and R. R. Reddel, Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines, Cancer Res, vol.47, pp.6180-6184, 1987.

A. S. Tsao, N. Harun, and J. J. Lee, Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma, Clin Lung Cancer, vol.15, pp.197-201, 2014.

R. Jagadeeswaran, P. C. Ma, and T. Y. Seiwert, Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma, Cancer Res, vol.66, pp.352-61, 2006.

W. B. Ou, J. M. Corson, and D. L. Flynn, AXL regulates mesothelioma proliferation and invasiveness, Oncogene, vol.30, pp.1643-52, 2011.

J. D. Paccez, M. Vogelsang, and M. I. Parker, The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications, Int J Cancer, vol.134, pp.1024-1057, 2014.

B. A. Jacobson, A. De, and M. G. Kratzke, Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma, Br J Cancer, vol.101, pp.424-455, 2009.

T. Plones, F. Beckers, and W. Engel-riedel, Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study, BMC research notes, vol.7, p.549, 2014.

L. A. Marek, T. K. Hinz, and A. Von-massenhausen, Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma, Mol Cancer Res, vol.12, pp.1460-1469, 2014.

K. J. Butnor, J. L. Burchette, and T. A. Sporn, The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature, Arch Pathol Lab Med, vol.128, pp.538-581, 2004.

A. E. Horvai, L. Li, and Z. Xu, c-Kit is not expressed in malignant mesothelioma, Mod Pathol, vol.16, pp.818-840, 2003.

W. B. Ou, C. Hubert, and J. M. Corson, Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma, Neoplasia, vol.13, pp.12-22, 2011.

K. Kawaguchi, H. Murakami, and T. Taniguchi, Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells, Carcinogenesis, vol.30, pp.1097-105, 2009.

C. W. Menges, Y. Chen, and B. T. Mossman, A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma, Genes Cancer, vol.1, pp.493-505, 2010.

L. Vintman, S. Nielsen, and A. Berner, Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells, Cancer, vol.103, pp.2427-2460, 2005.

J. Daubriac, J. Fleury-feith, and L. Kheuang, Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates, Cell Death and Differentiation, vol.16, pp.1146-55, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00388174

S. Zhou, L. Liu, and H. Li, Multipoint targeting of the PI3K/mTOR pathway in mesothelioma, Br J Cancer, vol.110, pp.2479-88, 2014.

C. W. Menges, E. Sementino, and J. Talarchek, Group I p21-Activated Kinases

, Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf-MAPK Pathways, Mol Cancer Res, vol.10, pp.1178-88, 2012.

R. Eguchi, Y. Fujimori, and H. Takeda, Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells, J Cell Physiol, vol.226, pp.762-770, 2011.

K. Kryeziu, U. Jungwirth, and M. A. Hoda, Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair, Mol Cancer Ther, vol.12, pp.1073-84, 2013.

L. V. De-assis, J. Locatelli, and M. C. Isoldi, The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma, Biochim Biophys Acta, vol.1845, pp.232-279, 2014.

Y. Suzuki, H. Murakami, and K. Kawaguchi, Activation of the PI3K-AKT pathway in human malignant mesothelioma cells, Molecular Medicine Reports, vol.2, pp.181-189, 2009.

A. Besson, S. M. Robbins, and V. W. Yong, PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis, Eur J Biochem, vol.263, pp.605-616, 1999.

S. Cedres, M. A. Montero, and P. Martinez, Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM), Lung Cancer, vol.77, pp.192-200, 2012.

B. Fischer, C. Frei, and U. Moura, Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy, Lung Cancer, vol.78, pp.23-32, 2012.

D. A. Altomare, H. You, and G. H. Xiao, Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth, Oncogene, vol.24, pp.6080-6089, 2005.

V. Agarwal, A. Campbell, and K. L. Beaumont, PTEN protein expression in malignant pleural mesothelioma, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.34, pp.847-51, 2013.

I. Opitz, A. Soltermann, and M. Abaecherli, PTEN expression is a strong predictor of survival in mesothelioma patients, Eur J Cardiothorac Surg, vol.33, pp.502-508, 2008.

R. Kanteti, I. Dhanasingh, and I. Kawada, MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma, PLoS ONE, vol.9, p.105919, 2014.

B. Gao and P. P. Roux, Translational control by oncogenic signaling pathways, Biochim Biophys Acta, 2014.

C. Porta, C. Paglino, and A. Mosca, Targeting PI3K/Akt/mTOR Signaling in Cancer, Frontiers in oncology, vol.4, p.64, 2014.

K. Xu, P. Liu, and W. Wei, mTOR signaling in tumorigenesis, Biochim Biophys Acta, vol.1846, pp.638-54, 2014.

D. Barbone, T. M. Yang, and J. R. Morgan, Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids, J Biol Chem, vol.283, pp.13021-1330, 2008.

E. Ranzato, S. Grosso, and M. Patrone, Spreading of mesothelioma cells is rapamycinsensitive and requires continuing translation, J Cell Biochem, vol.108, pp.867-76, 2009.

S. M. Wilson, D. Barbone, and T. M. Yang, mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids, Am J Respir Cell Mol Biol, vol.39, pp.576-83, 2008.

G. Pinton, A. G. Manente, and G. Angeli, Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma, PLoS ONE, vol.7, p.36856, 2012.

M. A. Lopez-lago, T. Okada, and M. M. Murillo, Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling, Mol Cell Biol, vol.29, pp.4235-4284, 2009.

Y. Sekido, Molecular pathogenesis of malignant mesothelioma, Carcinogenesis, vol.34, pp.1413-1422, 2013.

J. Hao, Y. Zhang, and Y. Wang, Role of extracellular matrix and YAP/TAZ in cell fate determination, Cell Signal, vol.26, pp.186-91, 2014.

S. Piccolo, S. Dupont, and M. Cordenonsi, The biology of YAP/TAZ: hippo signaling and beyond, Physiol Rev, vol.94, pp.1287-312, 2014.

X. Varelas, The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease, Development, vol.141, pp.1614-1640, 2014.

H. Murakami, T. Mizuno, and T. Taniguchi, LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma, Cancer Res, vol.71, pp.873-83, 2011.

T. Mizuno, H. Murakami, and M. Fujii, YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes, Oncogene, vol.31, pp.5177-5199, 2012.

I. Tanaka, H. Osada, and M. Fujii, LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade, Oncogene, vol.34, pp.73-83, 2015.

M. Guled, L. Lahti, and P. M. Lindholm, CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis, Genes Chromosomes Cancer, vol.48, pp.615-638, 2009.

C. Thurneysen, I. Opitz, and S. Kurtz, Functional inactivation of NF2/merlin in human mesothelioma, Lung Cancer, vol.64, pp.140-147, 2009.

E. Yao and P. T. Chuang, Hedgehog signaling: From basic research to clinical applications, Journal of the Formosan Medical Association = Taiwan yi zhi, 2015.

C. B. Lim, C. M. Prele, and H. M. Cheah, Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma, PLoS ONE, vol.8, p.66685, 2013.

H. Li, N. Lui, and T. Cheng, Gli as a novel therapeutic target in malignant pleural mesothelioma, PLoS ONE, vol.8, p.57346, 2013.

Y. Shi, U. Moura, and I. Opitz, Role of hedgehog signaling in malignant pleural mesothelioma, Clin Cancer Res, vol.18, pp.4646-56, 2012.

M. You, J. Varona-santos, and S. Singh, Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro, J Thorac Cardiovasc Surg, vol.147, pp.508-524, 2014.

C. Y. Logan and R. Nusse, The Wnt signaling pathway in development and disease. Annual review of cell and developmental biology, vol.20, pp.781-810, 2004.

M. Kobayashi, C. L. Huang, and M. Sonobe, Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients. Experimental and therapeutic medicine, vol.3, pp.952-960, 2012.

S. A. Fox, A. K. Richards, and I. Kusumah, Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells, Biochem Biophys Res Commun, vol.440, pp.82-89, 2013.

J. Mazieres, L. You, and B. He, Wnt2 as a new therapeutic target in malignant pleural mesothelioma, Int J Cancer, vol.117, pp.326-358, 2005.

Y. Kashiwakura, K. Ochiai, and M. Watanabe, Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis, Cancer Res, vol.68, pp.8333-8374, 2008.

W. Anani, R. Bruggeman, and D. S. Zander, beta-catenin expression in benign and malignant pleural disorders, Int J Clin Exp Pathol, vol.4, pp.742-749, 2011.

G. V. Gee, D. C. Koestler, and B. C. Christensen, Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma, Int J Cancer, vol.127, pp.2859-69, 2010.

J. Liu, S. Shaik, and X. Dai, Targeting the ubiquitin pathway for cancer treatment, Biochim Biophys Acta, vol.1855, pp.50-60, 2014.

J. Cooper, W. Li, and L. You, Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression, Science signaling, vol.4, p.6, 2011.

W. Li, J. Cooper, and L. Zhou, Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus, Cancer Cell, vol.26, pp.48-60, 2014.

M. Laplante and D. M. Sabatini, mTOR signaling at a glance, J Cell Sci, vol.122, pp.3589-94, 2009.

R. E. Favoni and T. Florio, Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma, Trends in pharmacological sciences, vol.32, pp.463-79, 2011.

R. A. Stahel, W. Weder, and E. Felley-bosco, Searching for targets for the systemic therapy of mesothelioma, Ann Oncol, 2015.

A. Mathy, P. Baas, and O. Dalesio, Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial, Lung Cancer, vol.50, pp.83-89, 2005.

J. Remon, N. Reguart, and J. Corral, Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies, Cancer Treat Rev, vol.41, pp.27-34, 2015.

S. H. Ou, J. Moon, and L. L. Garland, SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM), J Thorac Oncol, vol.10, pp.387-91, 2015.

W. G. Kaelin, The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, vol.5, pp.689-98, 2005.

I. M. Shapiro, V. N. Kolev, and C. M. Vidal, Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship, Science translational medicine, vol.6, pp.237-68, 2014.

E. Felley-bosco and R. Stahel, Hippo/YAP pathway for targeted therapy, Translational lung cancer research, vol.3, pp.75-83, 2014.

R. E. Favoni, A. Daga, and P. Malatesta, Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma, British journal of pharmacology, vol.166, pp.532-53, 2012.

B. Davidson, Prognostic factors in malignant pleural mesothelioma, Hum Pathol, 2015.

G. L. Ceresoli and P. A. Zucali, Anti-angiogenic therapies for malignant pleural mesothelioma, Expert Opin Investig Drugs, vol.21, pp.833-877, 2012.

F. Galateau-salle, G. Soit-ilg, A. , L. Stang, and N. , , 1998.

, Annales de pathologie, vol.34, pp.51-63, 2014.

R. K. Thomas, A. C. Baker, and R. M. Debiasi, High-throughput oncogene mutation profiling in human cancer, Nat Genet, vol.39, pp.347-51, 2007.

M. Cargnello and P. P. Roux, Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol Mol Biol Rev, vol.75, pp.50-83, 2011.

D. Pan, The hippo signaling pathway in development and cancer, Dev Cell, vol.19, pp.491-505, 2010.

Y. Sekido, Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation, Pathol Int, vol.61, pp.331-375, 2011.